Rodman & Renshaw Starts Imprimis Pharmaceuticals (IMMY) at Buy

November 28, 2016 7:50 AM EST Send to a Friend
Rodman & Renshaw initiated coverage on Imprimis Pharmaceuticals (NASDAQ: IMMY) with a Buy rating and a price target of $5.Analyst ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login